Patents by Inventor Peter Birk
Peter Birk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141011Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.Type: ApplicationFiled: December 15, 2023Publication date: May 2, 2024Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
-
Publication number: 20180251756Abstract: The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of: a) adding a linker molecule L to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added in step c).Type: ApplicationFiled: May 16, 2018Publication date: September 6, 2018Inventor: Peter Birk Rasmussen
-
Publication number: 20180163199Abstract: The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of: a) adding a linker molecule L to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added step c).Type: ApplicationFiled: January 30, 2018Publication date: June 14, 2018Inventor: Peter Birk Rasmussen
-
Patent number: 9371533Abstract: Disclosed is a DNA polynucleotide comprising a nucleic acid sequence having promoter activity in a Drosophila S2 cell, where said nucleic acid sequence is selected from (i) a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO: 37, or SEQ ID NO: 68 with or without flanking restriction site sequences at either terminus; (ii) a functional nucleotide sequence with a sequence identity of at least 80% to any one sequence of (i); (iii) a nucleotide which is a functional fragment of at least 6 contiguous nucleotides of any one sequence of (i) or (ii); (iv) a functional nucleotide sequence with a sequence identity of at least 80% to said functional fragment of (iii); (v) a first chimeric nucleotide sequence comprising two or more sequences of any one sequence of (i), (ii), (iii) and (iv), and (vi) a second chimeric nucleotide sequence, comprising at least 6 nucleotides and including consecutive nucleotide stretches from at leastType: GrantFiled: June 12, 2009Date of Patent: June 21, 2016Assignee: Expres2ion Biotechnologies ApSInventors: Charlotte Dyring, Willem Adriaan De Jongh, Peter Birk Rasmussen, Helene Lykkegaard
-
Publication number: 20150203841Abstract: The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of a) adding a linker molecule L to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added step c).Type: ApplicationFiled: April 1, 2015Publication date: July 23, 2015Inventor: Peter Birk Rasmussen
-
Publication number: 20150126381Abstract: The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of: a) adding a linker molecule L to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added in step c).Type: ApplicationFiled: January 6, 2015Publication date: May 7, 2015Inventor: Peter Birk Rasmussen
-
Battery powered electronic device comprising a movable part and adapted to be set into shipping mode
Patent number: 8983552Abstract: A battery powered electronic device (1) comprising a housing (2) and a movable part (3) extending from the housing (2). The movable part (3) is movably attached to the housing (2), such that it can be moved between a compact position and an extended position. The electronic device comprises a switch, which is adapted to sense, whether the movable part (3) is in the compact position or not, and the switch is utilized to switch the electronic device (1) On, when the movable part (3) is in the extended position, and Off, when the movable part (3) is in the compact position. The electronics of the device (1) is adapted to be set to off or into a low-power shipping mode, all though the movable part (3) is in the extended position.Type: GrantFiled: September 4, 2012Date of Patent: March 17, 2015Assignee: GN Netcom A/SInventors: Peter Birk Andersen, Michael Hoby Andersen, Tommy Sorensen, Jes Lundberg, Carsten Jurs -
Patent number: 8951728Abstract: The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of: a) adding a linker molecule L to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added in step c).Type: GrantFiled: October 30, 2013Date of Patent: February 10, 2015Assignee: ChemGene Holding ApSInventor: Peter Birk Rasmussen
-
Patent number: 8871212Abstract: Disclosed are novel methods and compositions for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A?). Immunization is preferably effected by administration of analogs of autologous APP or A?, said analogs being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A? which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Such methods and means include methods for the preparation of analogs and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.Type: GrantFiled: December 19, 2008Date of Patent: October 28, 2014Assignee: H. Lundbeck A/SInventors: Peter Birk Rasmussen, Martin Roland Jensen, Klaus Gregorius Nielsen, Peter Koefoed, Florence Dal Degan
-
Publication number: 20140235509Abstract: The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of a) adding a linker molecule L to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added step c).Type: ApplicationFiled: March 31, 2014Publication date: August 21, 2014Inventor: Peter Birk Rasmussen
-
Publication number: 20140066336Abstract: The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of: a) adding a linker molecule L to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added in step c).Type: ApplicationFiled: October 30, 2013Publication date: March 6, 2014Applicant: ChemGene Holding ApSInventor: Peter Birk Rasmussen
-
Publication number: 20130237459Abstract: The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of: a) adding a linker molecule L to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added in step c).Type: ApplicationFiled: April 9, 2012Publication date: September 12, 2013Inventor: Peter Birk RASMUSSEN
-
Battery Powered Electronic Device Comprising A Movable Part and Adapted to Be Set Into Shipping Mode
Publication number: 20130130749Abstract: A battery powered electronic device (1) comprising a housing (2) and a movable part (3) extending from the housing (2). The movable part (3) is movably attached to the housing (2), such that it can be moved between a compact position and an extended position. The electronic device comprises a switch, which is adapted to sense, whether the movable part (3) is in the compact position or not, and the switch is utilised to switch the electronic device (1) On, when the movable part (3) is in the extended position, and Off, when the movable part (3) is in the compact position. The electronics of the device (1) is adapted to be set to off or into a low-power shipping mode, all though the movable part (3) is in the extended position.Type: ApplicationFiled: September 4, 2012Publication date: May 23, 2013Applicant: GN Netcom A/SInventors: Peter Birk Andersen, Michael Hoby Andersen, Tommy Sorenen, Jes Lundberg, Carsten Jurs -
Patent number: 8168381Abstract: The present invention provides a method for combining the advantages of encoded molecule fragments made by split and mix synthesis with the advantages of template directed synthesis of molecules.Type: GrantFiled: November 22, 2005Date of Patent: May 1, 2012Inventor: Peter Birk Rasmussen
-
Patent number: 8076469Abstract: The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as diagnostic reagents containing the polypeptides.Type: GrantFiled: November 1, 2007Date of Patent: December 13, 2011Assignee: Statens Serum InstitutInventors: Peter Andersen, Karin Weldingh, Christina Veggerby Hansen, Walter Florio, Li Mei Meng Okkels, Rikke Louise Vinther Skjot, Peter Birk Rasmussen
-
Publication number: 20110136171Abstract: Disclosed is a DNA polynucleotide comprising a nucleic acid sequence having promoter activity in a Drosophila S2 cell, where said nucleic acid sequence is selected from (i) a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO: 37, or SEQ ID NO: 68 with or without flanking restriction site sequences at either terminus; (ii) a functional nucleotide sequence with a sequence identity of at least 80% to any one sequence of (i); (iii) a nucleotide which is a functional fragment of at least 6 contiguous nucleotides of any one sequence of (i) or (ii); (iv) a functional nucleotide sequence with a sequence identity of at least 80% to said functional fragment of (iii); (v) a first chimeric nucleotide sequence comprising two or more sequences of any one sequence of (i), (ii), (iii) and (iv), and (vi) a second chimeric nucleotide sequence, comprising at least 6 nucleotides and including consecutive nucleotide stretches from at leastType: ApplicationFiled: June 12, 2009Publication date: June 9, 2011Applicant: Expres2ion Biotechnologies ApSInventors: Charlotte Dyring, Willem Adriaan De Jongh, Peter Birk Rasmussen, Helene Lykkegaard
-
Patent number: 7820633Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: GrantFiled: May 19, 2003Date of Patent: October 26, 2010Assignee: BN Immunotherapeutics, Inc.Inventors: Lucilla Steinaa, Jesper Haaning, Iben Dalum, Peter Birk, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Anand Gautam, Søren Mouritsen
-
Patent number: 7807441Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: GrantFiled: August 11, 2005Date of Patent: October 5, 2010Assignee: BN Immunotherapeutics, Inc.Inventors: Lucilla Steinaa, Søren Mouritsen, Anand Gautam, Iben Dalum, Jesper Haaning, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Peter Birk Rasmussen
-
Publication number: 20100047262Abstract: Disclosed are novel methods and compositions for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A?). Immunization is preferably effected by administration of analogues of autologous APP or A?, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A? which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.Type: ApplicationFiled: December 19, 2008Publication date: February 25, 2010Inventors: Peter Birk Rasmussen, Martin Roland Jensen, Klaus Gregorius Nielsen, Peter Koefoed, Florence Dal Degan
-
Publication number: 20090311281Abstract: Disclosed are novel methods for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (A?). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A? which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of A?'s B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination.Type: ApplicationFiled: January 28, 2009Publication date: December 17, 2009Inventors: Martin Roland Jensen, Peter Birk, Klaus Gregorius Nielsen